Who manufactures UPTRAVI?
About UPTRAVI® (selexipag) Selexipag, a selective prostacyclin IP receptor agonist, is a compound discovered by Nippon Shinyaku and licensed to Actelion Pharmaceuticals Ltd outside Japan. It is licensed for the oral treatment of PAH in more than 60 countries.
What kind of drug is UPTRAVI?
UPTRAVI ® (selexipag) is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs. UPTRAVI ® can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.
Is UPTRAVI a specialty drug?
UPTRAVI® is distributed to patients by mail through a specialty pharmacy rather than through a retail pharmacy. When you enroll your patients, they are connected to a specialty pharmacy based on their health insurance plans or their healthcare teams’ preference.
Is UPTRAVI a prostacyclin?
Selexipag (Uptravi®) is an orally active, first-in-class, selective prostacyclin IP receptor agonist.
Does Uptravi lower blood pressure?
Uptravi (selexipag) lowers blood pressure in your lungs by dilating (widening) blood vessels that supply blood to the lungs. Uptravi is used to treat pulmonary arterial hypertension (PAH). Uptravi helps keep your condition from getting worse and helps lower your risk of needing to be hospitalized for PAH.
When does Uptravi patent expire?
Uptravi was eligible for patent challenges on December 21, 2019. By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 1, 2030….Summary for UPTRAVI.
| International Patents: | 144 |
|---|---|
| Drug Prices: | Drug price information for UPTRAVI |
What happens if you stop taking UPTRAVI?
If you forget to take UPTRAVI, take a dose as soon as you remember, then continue to take your tablets at the usual times. If it is nearly time for your next dose (within six hours before you would normally take it) you should skip the missed dose and continue to take your medicine at the usual time.
How is UPTRAVI administered?
Administer UPTRAVI for injection by intravenous infusion, twice daily. (2.2) See Full Prescribing Information for instructions on preparation and administration. (2.3). To report SUSPECTED ADVERSE REACTIONS, contact Janssen at 1-800-526-7736 (1-800-JANSSEN) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
How often do you take UPTRAVI?
Dosing of selexipag (Uptravi®) The starting dose of selexipag is 200 mcg twice daily. The dose is then increased by 200mcg twice daily every week to the highest dose a patient can tolerate up to a maximum dose of 1,600mcg twice daily.
Does UPTRAVI lower blood pressure?
Can UPTRAVI cause shortness of breath?
new lung problems–anxiety, sweating, pale skin, severe shortness of breath, wheezing, gasping for breath, cough with foamy mucus, chest pain, fast or uneven heart rate.
Is Selexipag generic?
Synopsis. Alembic’s product is the generic equivalent to the reference listed drug product (RLD) Uptravi. Alembic Pharmaceuticals on Wednesday said it has received approval from the US health regulator to market Selexipag tablets, used to treat high blood pressure, in the American market.
What is the Uptravi® Patient Guide?
This guide helps you set goals and expectations with patients who are starting treatment with UPTRAVI®. It can be used as a conversation tool and is available to patients to help them stay on treatment by tracking and sharing how they’re feeling with their healthcare team.
What is Uptravi® IASSIST?
UPTRAVI® may now be prescribed through iAssist, a web-based platform that streamlines the prescription and enrollment process. Instead of faxing individual enrollment forms and insurance information, data can be entered in one place online to minimize incomplete forms and multiple submissions.
Is there an alternate form for the Uptravi psmn form?
Note: An alternate form is available for Veteran Affairs (VA) patients UPTRAVI® VA Prescription and Statement of Medical Necessity Form. This guide provides detailed instructions to help you fill out the UPTRAVI® PSMN Form.
What is the Uptravi® carepath oral PAH savings program?
Janssen CarePath Oral PAH Savings Program can help eligible patients save on their out-of-pocket medication costs for UPTRAVI®. Depending on their health insurance plan, savings may apply toward co-pay, co-insurance, or deductible.